Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types

Regeneron Pharmaceuticals, Inc. and Checkmate Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on proprietary technology to harness the power of the immune system to combat cancer, announced a definitive agreement for the acquisition of Checkmate by Regeneron.